Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.50 |
| ▸ | NMBR | P28336 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8889717 | 1.00 | TYR (0.55) | TYRITGB3ITGA2BTACR1CTRB1 | |
| SCHEMBL30825625 | 0.90 | ALDH1A1 (0.58) | TYRTACR1CTRB1CTSKCTSL | |
| SCHEMBL8674043 | 0.90 | ALDH1A1 (0.58) | TYRTACR1CTRB1CTSKCTSL | |
| SCHEMBL9001867 | 0.88 | TYR (0.49) | TYRITGB3ITGA2BTACR1CTRB1 | |
| SCHEMBL9001865 | 0.88 | TYR (0.49) | TYRITGB3ITGA2BTACR1CTRB1 | |
| SCHEMBL220648 | 0.86 | TACR1 (0.68) | TYRITGB3ITGA2BTACR1CTRB1 | |
| SCHEMBL219151 | 0.86 | TACR1 (0.68) | TYRITGB3ITGA2BTACR1CTRB1 | |
| SCHEMBL7372270 | 0.86 | TACR1 (0.68) | TYRITGB3ITGA2BTACR1CTRB1 | |
| SCHEMBL479010 | 0.86 | TACR1 (0.68) | TYRITGB3ITGA2BTACR1CTRB1 | |
| SCHEMBL26661077 | 0.86 | TACR1 (0.68) | TYRITGB3ITGA2BTACR1CTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132524-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS, LLC | 2024-04-25 | — | — | US | disclosed |
| WO-2024064210-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS, LLC (US) | 2024-03-28 | — | — | WO | disclosed |
| EP-0237082-B1 | 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | disclosed |
| US-4929630-A | SKIN DISORDERS, ACNE, 4,5-DIHYDROISOOXAZOLE PEPTIDES | SYNTEX (U.S.A.) INC. (US) | 1990-05-29 | — | — | US | disclosed |
| US-4912120-A | Containing amine and amide substitution | SYNTEX (U.S.A.) INC. (US) | 1990-03-27 | — | — | US | disclosed |
| EP-0237082-A2 | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132524-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | NME2, BTD, BLVRB | TYR 3455/4885ITGB3 3125/4885ITGA2B 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.